Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
25.97
-0.64 (-2.41%)
At close: Jul 19, 2024, 4:00 PM
25.98
+0.01 (0.04%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Myriad Genetics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Myriad Genetics stock have an average target of 25, with a low estimate of 14 and a high estimate of 35. The average target predicts a decrease of -3.74% from the current stock price of 25.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MYGN stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $29 | Buy | Initiates | $29 | +11.67% | Jun 27, 2024 |
| Jefferies | Jefferies | Hold → Sell Initiates $25 → $20 | Hold → Sell | Initiates | $25 → $20 | -22.99% | Jun 3, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $23 → $28 | Hold | Maintains | $23 → $28 | +7.82% | May 13, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $25 → $35 | Hold → Buy | Upgrades | $25 → $35 | +34.77% | May 8, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $31 | Strong Buy | Maintains | $28 → $31 | +19.37% | Jan 30, 2024 |
Financial Forecast
Revenue This Year
848.49M
from 753.20M
Increased by 12.65%
Revenue Next Year
913.02M
from 848.49M
Increased by 7.61%
EPS This Year
0.03
from -3.18
EPS Next Year
0.22
from 0.03
Increased by 579.89%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 878.9M | 960.0M | 1.1B | 1.2B | 1.3B |
| Avg | 848.5M | 913.0M | 976.7M | 1.0B | 1.1B |
| Low | 808.5M | 849.6M | 867.2M | 904.9M | 938.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.7% | 13.1% | 15.7% | 19.0% | 23.5% |
| Avg | 12.7% | 7.6% | 7.0% | 6.0% | 4.5% |
| Low | 7.3% | 0.1% | -5.0% | -7.3% | -9.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.05 | 0.39 | 0.79 | 0.71 | 1.38 |
| Avg | 0.03 | 0.22 | 0.43 | 0.43 | 0.61 |
| Low | - | 0.03 | 0.20 | -0.05 | -0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,098.9% | 257.4% | 65.7% | 221.1% |
| Avg | - | 579.9% | 95.6% | -0.6% | 42.1% |
| Low | - | -9.3% | -11.0% | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.